Table 2.

TLS Risk Stratification and Prophylaxis Strategy by TLS Risk

	Low Risk n=118		Intermediate Risk n=94		High Risk n=83		Total Cohort n=297
Risk Stratification	% (unless noted)	Number with Available Data	% (unless noted)	Number with Available Data	% (unless noted)	Number with Available Data	% (unless noted)	Number with Available Data
CT Scan	55%	89	65%	68	76%	33	62%,	190
Largest Lymph Node
< 5 cm	93%	90	58%	66	30%	33	71%	189
5 to 10 cm	7%	90	41%	66	28%	33	22%	189
>10 cm	0%	90	2%	66	42%	33	8%	189
ALC, median (range)	3000/μL (100–46,000/μL)	76	27,000/μL (60–201,000/μL)	56	35,100/μL (700–326,000/μL)	31	9000/μL (60–326,600/μL)	164
Planned Hospitalizations							n=265
0	43%	101	20%	82	12%	80	27%	265
1	18%	101	29%	82	23%	80	23%	265
2	18%	101	28%	82	36%	80	26%	265
3	5%	101	10%	82	11%	80	8%	265
4	6%	101	5%	82	6%	80	6%	265
5	10%	101	8%	82	9%	80	9%	265
6	0%	101	0%	82	3%	80	1%	265
Prophylaxis
Allopurinol	91%	75	93%	56	94%,	31	92%	163
Rasburicase	27%	102	42%	81	72%	79	45%	264
Normal Saline	85%	73	88%	56	97%	31	88%	161
Outcomes
Clinical TLS	n=2	117	n=3	94	n=3	83	2.7%	296
Laboratory TLS	n=3	117	n=7	94	n=7	83	5.7%	296
Requiring HD	n=0	117	n=1	94	n=0	83	0.3%	296
Deaths attributable to TLS	n=0	118	n=0	94	n=1	83	0.8%	125

ALC = absolute lymphocyte count; TLS = tumor lysis syndrome; HD = hemodialysis